{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=2&q=BRAF",
    "query": {
      "q": "BRAF",
      "condition": "Melanoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=1&q=BRAF&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T05:01:24.405Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01840527",
      "title": "Utility of Novel BRAF Test for Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2013-05",
      "completion_date": "2022-09",
      "has_results": true,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01840527"
    },
    {
      "nct_id": "NCT01941927",
      "title": "Trametinib With GSK2141795 in BRAF Wild-type Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Trametinib (GSK1120212)",
          "type": "DRUG"
        },
        {
          "name": "GSK2141795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adil Daud",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-09-10",
      "completion_date": "2017-05-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • New York, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01941927"
    },
    {
      "nct_id": "NCT03415126",
      "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Malignancy",
        "Neoplasia",
        "Neoplasm",
        "Neoplasm Metastasis",
        "Colon Cancer",
        "Colonic Neoplasms",
        "Colon Cancer Liver Metastasis",
        "Metastatic Cancer",
        "Metastatic Melanoma",
        "Metastatic Colon Cancer",
        "Metastatic Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreas Adenocarcinoma",
        "Pancreas Neoplasm",
        "Metastatic Nonsmall Cell Lung Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ASN007: ascending doses",
          "type": "DRUG"
        },
        {
          "name": "ASN007 RD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asana BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-01-19",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415126"
    },
    {
      "nct_id": "NCT02065063",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2014-04-22",
      "completion_date": "2016-06-23",
      "has_results": false,
      "last_update_posted_date": "2018-06-01",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065063"
    },
    {
      "nct_id": "NCT02012231",
      "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Thyroid Cancer",
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Histiocytosis",
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "PLX8394",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fore Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2014-02",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012231"
    },
    {
      "nct_id": "NCT02587650",
      "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK Fusion Protein Expression",
        "BRAF wt Allele",
        "Invasive Skin Melanoma",
        "MET Fusion Gene Positive",
        "NRAS wt Allele",
        "NTRK1 Fusion Positive",
        "NTRK2 Fusion Positive",
        "NTRK3 Fusion Positive",
        "RET Fusion Positive",
        "ROS1 Fusion Positive",
        "Stage III Cutaneous Melanoma",
        "Stage IIIA Cutaneous Melanoma",
        "Stage IIIB Cutaneous Melanoma",
        "Stage IIIC Cutaneous Melanoma",
        "Stage IV Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Capmatinib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-03-26",
      "completion_date": "2018-07-12",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587650"
    },
    {
      "nct_id": "NCT01954043",
      "title": "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib 150 mg twice a day (BID)",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole 40 mg once daily (OD)",
          "type": "DRUG"
        },
        {
          "name": "Rifampin 600 mg OD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-12-20",
      "completion_date": "2016-02-29",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 3,
      "location_summary": "Goodyear, Arizona • Dallas, Texas • Tacoma, Washington",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954043"
    },
    {
      "nct_id": "NCT04557956",
      "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Tazemetostat Hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-08-19",
      "completion_date": "2027-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 17,
      "location_summary": "Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557956"
    },
    {
      "nct_id": "NCT01378975",
      "title": "A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2011-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01378975"
    },
    {
      "nct_id": "NCT02974725",
      "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "LXH254",
          "type": "DRUG"
        },
        {
          "name": "LTT462",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-02-24",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-07-24T05:01:24.405Z",
      "location_count": 6,
      "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974725"
    }
  ]
}